ライフサイエンスコーパス: malignant melanoma

1 ted with clinical PD-L1 expression scores in malignant melanoma.

2 nt aetiological factor in the development of malignant melanoma.

3 rgeted treatment strategies are required for malignant melanoma.

4 Dermal invasion is a hallmark of malignant melanoma.

5 inding benzamide in patients with metastatic malignant melanoma.

6 e ionotropic glutamate receptors, GRIN2A, in malignant melanoma.

7 notropic glutamate receptor signaling has in malignant melanoma.

8 S100B is a prognostic marker for malignant melanoma.

9 ression of precursor melanocytic lesions and malignant melanoma.

10 sence and functional implications of IgG4 in malignant melanoma.

11 trategy for challenging environments such as malignant melanoma.

12 portant environmental factor associated with malignant melanoma.

13 ors that may exhibit histologic overlap with malignant melanoma.

14 s occurred, representing 33% of all incident malignant melanoma.

15 c signaling in the majority of patients with malignant melanoma.

16 tor for CCL1, is strongly expressed by human malignant melanoma.

17 tial therapeutic strategies for treatment of malignant melanoma.

18 raging for applications in breast cancer and malignant melanoma.

19 monly used to treat patients with metastatic malignant melanoma.

20 stulated to contribute to the elimination of malignant melanoma.

21 L ULBP2 as strong prognostic marker in human malignant melanoma.

22 dramatic clinical responses in patients with malignant melanoma.

23 oH2A (mH2A) suppresses tumour progression of malignant melanoma.

24 g established in vitro and in vivo models of malignant melanoma.

25 utical for treating patients with metastatic malignant melanoma.

26 V1 may function as an antimetastatic gene in malignant melanoma.

27 B-p53 interaction as a strategy for treating malignant melanoma.

28 several human malignancies, including human malignant melanoma.

29 n cancer, breast cancer, bladder cancer, and malignant melanoma.

30 (18)F-labeled probe for PET of MC1R-positive malignant melanoma.

31 nctions as a "lineage addiction" oncogene in malignant melanoma.

32 tion and restoring wild-type p53 function in malignant melanoma.

33 ients with macroscopic nodal metastases from malignant melanoma.

34 e cancer/testis Ag NY-ESO-1 in patients with malignant melanoma.

35 lic activity in many cancer types, including malignant melanoma.

36 development of bortezomib and IFN-alpha for malignant melanoma.

37 H(Arg(11)) an ideal candidate for the PET of malignant melanoma.

38 ives rise to genomically unstable progeny in malignant melanoma.

39 invasive ductal carcinoma of the breast, and malignant melanoma.

40 nt, and has been described as an oncogene in malignant melanoma.

41 nevi represents an important risk factor for malignant melanoma.

42 ge and identify treatments for patients with malignant melanoma.

43 (PET) imaging would aid in the detection of malignant melanoma.

44 porter and chemoresistance mediator in human malignant melanoma.

45 cs and targeting therapies for patients with malignant melanoma.

46 be useful for the treatment of patients with malignant melanoma.

47 ignificant antitumor responses in a model of malignant melanoma.

48 play an important role in the progression of malignant melanoma.

49 recently been discovered as driver events in malignant melanoma.

50 AC inhibition may thus be key to treating malignant melanoma.

51 lecular determinants of cytoarchitecture, in malignant melanoma.

52 significantly reflects mutation frequency in malignant melanoma.

53 forming the prognosis for many patients with malignant melanoma.

54 lanocytic lesions, only some of which become malignant melanoma.

55 ed as exposures, and the primary outcome was malignant melanoma.

56 on factor FOXM1 is elevated and activated in malignant melanoma.

57 y a combination of rFVIIa and factor F(X) in malignant melanoma.

58 thane extract of W. tinctoria leaves against malignant melanoma.

59 statistically significant increased risk of malignant melanoma.

60 valuated as a chemotherapeutic agent against malignant melanoma.

61 f a pathway implicated in the development of malignant melanoma.

62 for the H2A.Z isoform H2A.Z.2 as a driver of malignant melanoma.

63 RSK signaling and increased cell survival in malignant melanoma.

64 ic agent for PET and radionuclide therapy of malignant melanoma.

65 des a genetic approach to predict outcome in malignant melanomas.

66 rst description of chromothripsis in primary malignant melanomas.

67 xpressed by both benign melanocytes and many malignant melanomas.

68 ism of regulation of MITF in melanocytes and malignant melanomas.

69 (also known as BRAF) are found in 50-70% of malignant melanomas.

70 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas.

71 inhibited by Ca(2+)-binding S100 proteins in malignant melanomas.

72 that this gene is epigenetically silenced in malignant melanomas.

73 underwent enucleation surgery for choroidal malignant melanomas.

74 or the regulation of MITF in melanocytes and malignant melanomas.

75 ion (V600E) is found in more than 50% of all malignant melanomas.

76 as pain, inflammation, airway diseases, and malignant melanomas.

77 95% CI 1.19-1.30), rectum (1.14, 1.07-1.22), malignant melanoma (1.32, 1.24-1.40), breast (1.17, 1.15

78 s (24/32), basal cell carcinomas (30/31) and malignant melanomas (15/15), and provide evidence for a

79 5 sebaceous cell carcinomas [31.25%], and 4 malignant melanomas [25%]) were included in the study.

80 We compared 10 patients who died of malignant melanoma 3.7 years (median, range 0.9-7.6 year

81 me in cell replication, were investigated in malignant melanoma, a cancer with a paucity of effective

82 chromatin that suppresses the development of malignant melanoma, a highly intractable cutaneous neopl

83 C3), whereas 1.47 muM was observed for human malignant melanoma (A375) cells.

84 whereas an increased incidence was found for malignant melanoma among both men (SIR = 1.09) and women

85 Here we have sequenced the genomes of a malignant melanoma and a lymphoblastoid cell line from t

86 imple, accurate, in vivo distinction between malignant melanoma and atypical nevi, and may lead to a

87 In NICD(OE-HEC) mice, hepatic metastasis of malignant melanoma and colorectal carcinoma was signific

88 HRH receptors in surgical specimens of human malignant melanoma and evaluated the effects of AN-207 i

89 fter diagnosis with 10 patients who survived malignant melanoma and had a median disease-free surviva

90 and the role of miRNA in the pathogenesis of malignant melanoma and identify biomarkers of metastasis

91 ve and active immunotherapy in patients with malignant melanoma and neuroblastoma.

92 EF-hand proteins that has been implicated in malignant melanoma and neurodegenerative conditions such

93 ve revolutionized the clinical management of malignant melanoma and now offer hope to patients with a

94 and effective role in the future control of malignant melanoma and other cancers.

95 ase may have broad applications for treating malignant melanoma and potentially other cancer types.

96 l relevance of different mouse Slfn genes in malignant melanoma and renal cell carcinoma cells.

97 ession of members of this family of genes in malignant melanoma and renal cell carcinoma.

98 eoplastic syndrome associated with cutaneous malignant melanoma and the presence of autoantibodies th

99 lls, granulosa cell tumours, and a subset of malignant melanoma and thyroid cancers.

100 into the tumor suppressive role of PARK2 in malignant melanoma and uncover a novel mechanism for the

101 inhibition of RAF is already established in malignant melanoma and under investigation in non-small-

102 thway), is highly expressed in primary human malignant melanomas and melanoma cell lines with activat

103 BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase acti

104 n to evidence of multiple GISTs, lentigines, malignant melanoma, and an angioleiomyoma were identifie

105 h Cholesterol, Asthma, Basal Cell Carcinoma, Malignant Melanoma, and Heart Attack.

106 use is associated with an increased risk of malignant melanoma, and whether any increase in risk is

107 utations occur in approximately 70% of human malignant melanomas, and a single hyperactivating V600E

108 EK-ERK pathway is deregulated in over 90% of malignant melanomas, and targeting MEK as a central kina

109 ng antibodies to augment T-cell responses to malignant melanoma are at an advanced stage; however, li

110 Highly immunogenic cancers such as malignant melanoma are capable of inexorable tumor growt

111 Hallmarks of malignant melanoma are its propensity to metastasize and

112 lignant melanoma in situ (MMIS) and invasive malignant melanoma are rising in the United States, but

113 , we report 4 cases of orbital recurrence of malignant melanoma as a late complication of biopsy and/

114 man and murine melanoma cell lines, in human malignant melanoma, as well as in metastatic melanoma in

115 rospectively evaluated the risk of cutaneous malignant melanoma associated with citrus consumption.

116 Malignant melanomas associated with good prognosis showe

117 When it escapes early detection, malignant melanoma becomes a highly lethal and treatment

118 log (NRAS) gene are common genetic events in malignant melanoma being found in 15-25% of cases.

119 on specific cancer cell lines, in particular malignant melanoma, breast cancer, and leukemia.

120 p53 protein complex was discovered in C8146A malignant melanoma, but the consequences of this interac

121 es, has the potential for early detection of malignant melanoma by exploiting the sensitivity and hig

122 hat PDE5 inhibitors may increase the risk of malignant melanoma by negating newly identified brakes o

123 ell degranulation, but a deleterious role in malignant melanoma, by impeding IgG1-mediated anti-tumor

124 In its early stages malignant melanoma can be cured by surgical resection, b

125 ukin (IL)-2, a T-cell cytokine used to treat malignant melanoma, can induce profound depression.

126 gh response rates and profound regression of malignant melanomas carrying BRAF(V600E) mutations.

127 For malignant melanoma cases with recorded thickness, the pr

128 atasets, which consist of 800 benign and 200 malignant melanoma cases.

129 512 that can target both the stromal and the malignant melanoma cell compartments.

130 o have significant activity in the Sk-Mel-28 malignant melanoma cell line (IC(50) values of 1.10 and

131 proliferative action of eugenol in the human malignant melanoma cell line, WM1205Lu, showed that it a

132 play essential roles in the control of mouse malignant melanoma cell proliferation and/or anchorage-i

133 ase-dependent cell death in a panel of human malignant melanoma cells (A375, G361, LOX-IMVI) but not

134 Human malignant melanoma cells (which express VEGFR-2 but not

135 FN5, SLFN11, SLFN12, SLFN13, and SLFN14), in malignant melanoma cells and primary normal human melano

136 Indeed, malignant melanoma cells exhibit elevated DNFA gene expr

137 Highly malignant melanoma cells express the highest levels of E

138 exerts potent inhibitory activities against malignant melanoma cells in vitro and in vivo, but the m

139 BRAF and that block paradoxical signaling in malignant melanoma cells occurring through this drug tar

140 in situ contain a high level of HDAC1/2 and malignant melanoma cells overexpress HDAC1/2/3 compared

141 Importantly, stable knockdown of SLFN5 in malignant melanoma cells resulted in increased anchorage

142 logic inhibition of class I HDACs sensitizes malignant melanoma cells to apoptosis following exposure

143 e impact of class I HDACs on the response of malignant melanoma cells treated with alkylating agents.

144 gest feasibility of apoptotic elimination of malignant melanoma cells using the quinone methide-deriv

145 tional capacity of normal human melanocytes, malignant melanoma cells, and metastatic melanoma cells

146 we study the phenomena of immune evasion in malignant melanoma cells.

147 GIGILTV) antigen expressed on the surface of malignant melanoma cells.

148 reduced KiSS-1 promoter activation in highly malignant melanoma cells.

149 EphB4 receptor and migrate faster than less malignant melanoma cells.

150 Known high-risk cutaneous malignant melanoma (CMM) genes account for melanoma risk

151 The incidence of cutaneous malignant melanoma (CMM) has more than doubled in the pa

152 underlying the high prevalence of cutaneous malignant melanoma (CMM) in Parkinson disease (PD) are u

153 i (DN) is a strong risk factor for cutaneous malignant melanoma (CMM), and it frequently occurs in me

154 ion genes have been identified for cutaneous malignant melanoma (CMM), but they account for only appr

155 nmental risk factor for developing cutaneous malignant melanoma (CMM).

156 been reproducibly associated with cutaneous malignant melanoma (CMM).

157 re present in approximately 50% of cutaneous malignant melanomas (CMMs).

158 factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and medi

159 sera obtained from a subset of patients with malignant melanoma, compared with healthy control indivi

160 The incidence of cutaneous malignant melanoma continues to increase every year, and

161 Malignant melanoma continues to remain a significant hea

162 tem cell phenotype-expressing tumor cells in malignant melanoma cultures and clinical melanomas.

163 bladder cancer, renal cell cancer (RCC), and malignant melanoma data in 635 adult (>18 years of age)

164 Malignant melanoma developed within the giant nevus in 1

165 The English literature reports 16 cases of malignant melanoma developing in tattoos.

166 All 224 cases of malignant melanoma diagnosed in patients aged 10-24 year

167 In total, 1,315 incident malignant melanoma diagnoses were observed during 3.44 m

168 uired at the transition from benign nevus to malignant melanoma do not support telomere maintenance.

169 ka (Oryzias latipes), that overexpresses the malignant melanoma driver gene xmrk, a mutant egfr gene,

170 known about the role of CD82 tetraspanins in malignant melanomas during cancer cell invasion.

171 This study demonstrates that in malignant melanoma, elevated levels of nuclear beta-cate

172 w, we focus on the role of RAC1 signaling in malignant melanoma, emphasizing recent advances that des

173 Malignant melanoma exomes from 64 patients treated with

174 Malignant melanomas harbouring point mutations (Val600Gl

175 Malignant melanoma has an unusual propensity to metastas

176 Malignant melanoma has become an increasing interdiscipl

177 The incidence of malignant melanoma has dramatically increased in recent

178 The incidence of malignant melanoma has significantly increased over the

179 f cell proliferation and drug sensitivity in malignant melanoma, holding translational potential for

180 Using tissue sections from patients with malignant melanoma, immunofluorescence studies for the p

181 between increased BMI and rectal cancer and malignant melanoma in men; postmenopausal breast, pancre

182 nt report, we evaluated the growth of B16F10 malignant melanoma in mice with a monocyte/macrophage-se

183 y, PKCalpha has been linked to metastasis of malignant melanoma in patients.

184 Cutaneous malignant melanoma in Sinclair swine is a hereditary dis

185 The incidences of malignant melanoma in situ (MMIS) and invasive malignant

186 have shown great promise in the treatment of malignant melanoma in the last few years, with these dru

187 ion was associated with an increased risk of malignant melanoma in two cohorts of women and men.

188 this peptide was selectively exposed within malignant melanoma in vivo, whereas little if any was de

189 The data show that malignant melanomas in situ contain a high level of HDAC

190 shown that cyclin E is up-regulated in human malignant melanomas in vivo.

191 the role of B-Raf, the most mutated gene in malignant melanomas, in this process.

192 Tumorigenic ABCB5(+) malignant melanoma initiating cells (MMICs) possessed th

193 erline the importance of molecularly defined malignant melanoma initiating cells for CSC-focused diag

194 Malignant melanoma-initiating cells (MMIC) are a subpopu

195 Melanoma growth is driven by malignant melanoma-initiating cells (MMIC) identified by

196 identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by ex

197 In patients at high risk for recurrence of malignant melanoma, interferon-alpha (IFN-alpha), a stim

198 The pathogenesis of malignant melanoma involves the interplay of tumor cells

199 Malignant melanoma is a cancer that arises from melanocy

200 Late-stage malignant melanoma is a cancer that is refractory to cur

201 Malignant melanoma is a common and frequently lethal dis

202 Cutaneous malignant melanoma is a highly aggressive and frequently

203 Malignant melanoma is a highly aggressive neoplastic dis

204 Skin malignant melanoma is a highly angiogenic cancer, necess

205 sed on gene expression profiling showed that malignant melanoma is amenable to systemic treatment.

206 Cutaneous malignant melanoma is an aggressive cancer of melanocyte

207 Malignant melanoma is an aggressive skin cancer with poo

208 Hyperactivation of GRM1 in malignant melanoma is an oncogenic driver, which acts in

209 Early detection of malignant melanoma is associated with survival rates of

210 Malignant melanoma is characterized by a propensity for

211 Cutaneous malignant melanoma is considered one of the most deadly

212 le of radiotherapy for nodal metastases from malignant melanoma is controversial.

213 Evolution of conjunctival nevus into malignant melanoma is extremely low (<1%).

214 Malignant melanoma is frequently driven by mutational ac

215 The incidence of malignant melanoma is growing rapidly worldwide and ther

216 Cutaneous malignant melanoma is highly invasive and capable of met

217 Malignant melanoma is notorious for its inter- and intra

218 -BA52 as a novel approach for the therapy of malignant melanoma is of considerable potential.

219 Cutaneous malignant melanoma is one of the fastest increasing canc

220 Malignant melanoma is one of the most aggressive human c

221 Malignant melanoma is one of the most dangerous skin can

222 Cutaneous malignant melanoma is rapidly increasing in the develope

223 Malignant melanoma is the deadliest of skin cancers.

224 Malignant melanoma is the most aggressive form of cutane

225 Malignant melanoma is the most aggressive form of skin c

226 Malignant melanoma is the most invasive and deadly form

227 In malignant melanoma, its potential contribution to chemor

228 further evidence that molecular subtypes of malignant melanoma may develop along divergent pathways.

229 oma (BCC), squamous cell carcinoma (SCC), or malignant melanoma (MM) and comparative risk estimates o

230 gene is the most frequently mutated gene in malignant melanoma (MM) and papillary thyroid cancer (PT

231 A phase I study of patients with metastatic malignant melanoma (MM) and renal cell carcinoma (RCC) e

232 omplex formation with p53 ((Ca)S100B.p53) in malignant melanoma (MM) and restores p53 tumor suppresso

233 detection, dermatologists strive to diagnose malignant melanoma (MM) at the earliest possible stage.

234 In Denmark, the incidence of malignant melanoma (MM) has doubled during the past 25 y

235 Because fatality rates from malignant melanoma (MM) increase dramatically upon metas

236 Malignant melanoma (MM) is the most aggressive form of s

237 it sentinel lymph nodes (IMSLN) from primary malignant melanoma (MM) of the trunk.

238 In patients with lung cancer (LC), malignant melanoma (MM), gastroenteropancreatic neuroend

239 Those subsequently classified as malignant melanoma (MM), seborrheic keratosis (SK), and

240 Conditioned medium (CM) from metastatic malignant melanoma (MMM) cell lines attracted LEC migrat

241 Using the transgenic medaka malignant melanoma model, we established a screening sys

242 els, including the aggressive B16F10L murine malignant melanoma model.

243 h local recurrence and distant metastasis in malignant melanoma models.

244 onal nominally significant associations with malignant melanoma, multiple myeloma, oral cancer, and e

245 , PNL-2, and Melan-A) confirmed diagnosis of malignant melanoma of the ciliary body with extraocular

246 Fifty patients with primary malignant melanoma of the iris.

247 Malignant melanoma of the skin (CMM) is associated with

248 Malignant melanomas of the ciliary body with extraocular

249 ) lymphatic vessels were detected in 7 of 10 malignant melanomas of the ciliary body with extraocular

250 been investigated in patients with far rarer malignant melanomas of the female genital tract.

251 Malignant melanomas often harbor activating mutations in

252 Oral malignant melanoma (OMM) is the most common canine melan

253 Eighty patients with malignant melanoma on the trunk or extremities (upper an

254 idal tumors clinically as benign nevi versus malignant melanomas on the basis of tumor size appear li

255 consecutive days to patients with metastatic malignant melanoma or metastatic renal cell cancer.

256 othripsis with poor outcome in patients with malignant melanomas (P = 0.0002) and provides a genetic

257 ours (p=0.0046), astrocytomas (p=0.040), and malignant melanomas (p<0.0001).

258 cal significance of our results, we analyzed malignant melanoma patient samples with or without brisk

259 ased recurrence, and low overall survival in malignant melanoma patients.

260 ogen-activated protein kinase expression and malignant melanoma progression.

261 n the suppression of the HGF-MET pathway and malignant melanoma progression.

262 with histologically documented metastasized malignant melanoma received a single dose of 235 +/- 62

263 Similar to patients with malignant melanoma receiving high-dose IFN-alpha, the de

264 mechanisms underlying the intractability of malignant melanomas remain largely unknown.

265 The clinical management of malignant melanoma remains a challenge because these tum

266 Cutaneous malignant melanoma remains a therapeutic challenge, and

267 Metastatic malignant melanoma remains one of the most therapeutical

268 Malignant melanoma remains the deadliest form of skin ca

269 placement of tattoos and the development of malignant melanoma remains unclear.

270 Thus, a well known marker for malignant melanoma, S100B, likely contributes to cancer

271 ss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses

272 suppressor activity in cancer cells such as malignant melanoma, so a search for small molecules that

273 Human malignant melanoma specimen analyses revealed a strong c

274 expressed in a very high percentage of human malignant melanoma specimens and can be used for targete

275 ivation of BRAF is a frequent event in human malignant melanomas suggesting that BRAF-dependent signa

276 We describe the first case of a malignant melanoma that developed on a preexisting nevus

277 in and beta-catenin as two of the markers of malignant melanoma that were down-regulated in Panx1-KD

278 mparative genomic hybridization (aCGH) to 20 malignant melanomas that showed, despite comparable conv

279 Malignant melanoma, the most aggressive form of skin can

280 ion and the possible clinical implication on malignant melanoma therapy with temozolomide and other a

281 Consistently, Brca1 loss in human malignant melanoma tissues was found to be inversely cor

282 CT and prognosis in patients with metastatic malignant melanoma treated with ipilimumab.

283 ping roles for these genes in the control of malignant melanoma tumorigenesis.

284 n progenitor cells, is expressed in clinical malignant melanoma tumors and preferentially marks a sub

285 MSH), has the potential for the detection of malignant melanoma using PET.

286 hod for the detection and differentiation of malignant melanoma versus benign nevi.

287 omas versus benign seborrheic keratoses; and malignant melanomas versus benign nevi.

288 ific in vivo targeting of (18)F-FB-RMSH-1 to malignant melanoma was successfully achieved in preclini

289 mber of individuals with two or more primary malignant melanomas was not detected among the groups (P

290 Finally, using a model of malignant melanoma, we show that the oncogenic potential

291 node or in-transit metastasis from cutaneous malignant melanoma were randomly assigned to receive eit

292 ity criteria, only a few aspects--limited to malignant melanoma--were adaptable.

293 olet light exposure, a known risk factor for malignant melanoma, whereas the uneven distribution of m

294 We describe a patient with malignant melanoma who developed chronic lymphocytic leu

295 0201 patients at high risk for recurrence of malignant melanoma who received prolonged immunization w

296 to metastasize to the small bowel; however, malignant melanoma with metastatic spread to the appendi

297 al responses achieved by treating metastatic malignant melanoma with therapeutic modalities based on

298 and DGKI-BRAF fusion were identified in two malignant melanomas with a low mutational burden (number

299 or chromosome arm gains and losses, whereas malignant melanomas with poor prognosis harbored signifi

300 In all cases, histopathology confirmed malignant melanoma, with no intraepithelial component or